Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 5/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2571582 | 0.90 | MTOR (0.43) | CNR2FYNCECR2CNR1BRD4 | |
| SCHEMBL2570302 | 0.89 | MTOR (0.44) | CNR2FYNCECR2CNR1KCNH2 | |
| Hydrochloric Acid SCHEMBL2574144 | 0.89 | MTOR (0.42) | CNR2FYNCECR2CNR1KCNH2 | |
| Hydrochloric Acid SCHEMBL2573524 | 0.89 | MTOR (0.43) | CNR2FYNCECR2CNR1KCNH2 | |
| SCHEMBL2572048 | 0.87 | NR5A2 (0.42) | CNR2CNR1PDE10A | |
| SCHEMBL2571322 | 0.87 | CNR2 (0.41) | CNR2CNR1BRD4PDE10A | |
| SCHEMBL2577075 | 0.85 | MTOR (0.38) | CNR2FYNCECR2CNR1PDE10A | |
| SCHEMBL2573284 | 0.85 | CNR2 (0.42) | CNR2CNR1PDE10A | |
| SCHEMBL2569696 | 0.85 | MTOR (0.43) | CNR2FYNCECR2CNR1BRD4 | |
| SCHEMBL2570356 | 0.84 | KDM1A (0.39) | CNR2FYNCECR2CNR1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289502-A1 | IMIDAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-8273738-B2 | Imidazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2090570-B1 | IMIDAZOLE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-20100152178-A1 | IMIDAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-2090570-A1 | IMIDAZOLE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289502-A1 | IMIDAZOLE DERIVATIVES | CNR1, CNR2, ARRB1 | CNR2 2/4885FYN 675/4885CECR2 529/4885 |
| US-20100152178-A1 | IMIDAZOLE DERIVATIVES | CNR1, CNR2, ARRB1 | CNR2 2/4885FYN 675/4885CECR2 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.